N/A
Completed N=229
USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19
Source: ClinicalTrials.gov NCT04425850 ↗Enrolled (actual)
229
Serious AEs
0.0%
Results posted
Oct 2020
Primary outcomePrimary: Number of Infected Subjects — 0; 11 Participants — p=< 0.0001
Summary
Estimation of the prevalence and contagiousness of undocumented novel coronavirus infections is critical for understanding the overall prevalence and pandemic potential of this disease.
It is estimated that 86% of all infections were undocumented [95% credible interval (CI): 82-90%] before the 23 January 2020 travel restrictions. The transmission rate of undocumented infections per person was 55% the transmission rate of documented infections (95% CI: 46-62%), yet, because of their greater numbers, undocumented infections were the source of 79% of the documented cases.
Ivermectin + Carrageenan, taking advantage of their virucidal effects, are aimed at reducing the contagion.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Infected Subjects |
0; 11 | < 0.0001 sig |
| SECONDARY Adverse Events Other Than Those Resulting From Contagion or Disease Progression |
0; 0 | — |
Eligibility Criteria
Inclusion criteria
- Not younger than 18 years of either sex
- Health personnel from the Dr. Alberto Eurnekian Interzonal University Hospital
- No COVID-19 related symptoms
- Able to understand and give written informed consent
Exclusion criteria
- Known hypersensitivity or allergy to any component of the product under evaluation
- Age under 18 years
- Use of immunosuppressants (including systemic corticosteroids) in the past 30 days.
- Pregnant or nursing.
- Patients with other acute infectious diseases.
- Patients with autoimmune disease and / or decompensated chronic diseases.
- Unable to fulfill the administrative tasks proposed by the study.
- Infection with SARSCoV-2 confirmed by PCR or rapid test authorized by ANMAT.
Data sourced from ClinicalTrials.gov (NCT04425850). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.